5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional serotonin-specific reuptake inhibitors

Neuron Glia Biology

Volumn 6, Issue 2, 2010, Pages 113-125

  Zhang, Shiquen ^a   Li, Baoman ^a   Lovatt, Ditte ^b   Xu, Junnan ^a   Song, Dan ^a   Goldman, Steven A ^b   Nedergaard, Maiken ^b   Hertz, Leif ^a   Peng, Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Citalopram; cPLA2; ERK; fluorescence activated cell sorting; paroxetine

Indexed keywords

CITALOPRAM; CYTOSOLIC PHOSPHOLIPASE A2; FLUOXETINE; FLUVOXAMINE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PAROXETINE; SEROTONIN 2B RECEPTOR; SERTRALINE; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ARTICLE; ASTROCYTE; BRAIN; CELL ACTIVATION; CELL CULTURE; FLUORESCENCE ACTIVATED CELL SORTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR AFFINITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; METABOLISM; METHODOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ASTROCYTES; BRAIN; CELLS, CULTURED; FLOW CYTOMETRY; FLUOXETINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PAROXETINE; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN UPTAKE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 79951849932     PISSN: 1740925X     EISSN: 17410533     Source Type: Journal    
DOI: 10.1017/S1740925X10000141     Document Type: Article

References (62)

1. Birkenhager T.K., van den Broek W.W., Mulder P.G., Bruijn J.A. and Moleman P. (2004) Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. American Journal of Psychiatry 161, 2060-2065. (Pubitemid 39441407)
2. Bjerkenstedt L., Flyckt L., Overo K.F. and Lingjaerde O. (1985) Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. European Journal of Clinical Pharmacology 28, 553-557. (Pubitemid 15030781)
3. Bolden-Watson C. and Richelson E. (1993) Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Science 52, 1023-1029.
4. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G. and Macher J.P. (2000) Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23, 428-438.
5. Bonhaus D.W., Bach C., DeSouza A., Salazar F.H., Matsuoka B.D., Zuppan P. et al. (1995) The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors. British Journal of Pharmacology 115, 622-628.
6. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of proteindye binding. Analytical Biochemistry 72, 248-254.
7. Chen Y., Peng L., Zhang X., Stolzenburg J.U. and Hertz L. (1995) Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells. Brain Research Bulletin 38, 153-159.
8. Deecher D.C., Wilcox B.D., Dave V., Rossman P.A. and Kimelberg H.K. (1993) Detection of 5-hydroxytryptamine2 receptors by radioligand binding, northern blot analysis, and Ca2+ responses in rat primary astrocyte cultures. Journal of Neuroscience Research 35, 246-256. (Pubitemid 23182724)
9. DeVane C.L., Liston H.L. and Markowitz J.S. (2002) Clinical pharmacokinetics of sertraline. Clinical Pharmacokinetics 41, 1247-1266. (Pubitemid 36026765)
10. El Marjou M., Montalescot V., Buzyn A. and Geny B. (2000) Modifications in phospholipase D activity and isoform expression occur upon maturation and differentiation in vivo and in vitro in human myeloid cells. Leukemia 14, 2118-2127. (Pubitemid 32042251)
11. Etienne N., Schaerlinger B., Jaffre F. and Maroteaux L. (2004) [The 5-HT2B receptor: a main cardio-pulmonary target of serotonin]. Transforming Growth Factor Beta/Physiology 198, 22-29.
12. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M. et al. (2000) Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41-51.
13. Frazer A. (2001) Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. Journal of Clinical Psychiatry 62 Suppl 12, 16-23. (Pubitemid 32578703)
14. Freeman M.P., Nolan P.E. Jr., Davis M.F., Anthony M., Fried K., Fankhauser M. et al. (2008) Pharmacokinetics of sertraline across pregnancy and postpartum. Journal of Clinical Psychopharmacology 28, 646-653.
15. Hansson E., Simonsson P. and Alling C. (1987) 5-Hydroxytryptamine stimulates the formation of inositol phosphate in astrocytes from different regions of the brain. Neuropharmacology 26, 1377-1382. (Pubitemid 17154894)
16. Henry M.E., Schmidt M.E., Hennen J., Villafuerte R.A., Butman M.L., Tran P. et al. (2005) A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: a 19-F MRS study. Neuropsychopharmacology 30, 1576-1583. (Pubitemid 41153130)
17. Hertz L., Schousboe A., Boechler N., Mukerji S. and Fedoroff S. (1978) Kinetic characteristics of the glutamate uptake into normal astrocytes in cultures. Neurochemical Research 3, 1-14. (Pubitemid 8323615)
18. Hertz L. (2008) Bioenergetics of cerebral ischemia: a cellular perspective. Neuropharmacology 55, 289-309.
19. Hertz L., Bender A.S., Woodbury D.M. and White H.S. (1989) Potassium-stimulated calcium uptake in astrocytes and its potent inhibition by nimodipine. Journal of Neuroscience Research 22, 209-215. (Pubitemid 19092432)
20. Hertz L., Lovatt D., Goldman S.A. and Nedergaard M. (2010) Adrenoceptors in brain: cellular gene expression and effects on astrocytic metabolism and [Ca(2 + )](i). Neurochemistry International. April 7, Epub ahead of print.
21. Hertz L., Peng L. and Lai J.C. (1998) Functional studies in cultured astrocytes. Methods 16, 293-310.
22. Hirano K., Kimura R., Sugimoto Y., Yamada J., Uchida S., Kato Y. et al. (2005) Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. British Journal of Pharmacology 144, 695-702. (Pubitemid 40445618)
23. Hyttel J. (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). International Clinical Psychopharmacology 9 supp. 1, 19-26. (Pubitemid 24107713)
24. Hyttel J., Overo K.F. and Arnt J. (1984) Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology (Berlin) 83, 20-27. (Pubitemid 14141481)
25. Ivanov A.I., Pero R.S., Scheck A.C. and Romanovsky A.A. (2002) Prostaglandin E(2)-synthesizing enzymes in fever: differential transcriptional regulation. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 283, R1104-R1117. (Pubitemid 35216985)
26. Jusko W.J. and Gretch M. (1976) Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metabolism Reviews 5, 43-140.
27. Kent J.M., Coplan J.D., Lombardo I., Hwang D.R., Huang Y., Mawlawi O. et al. (2002) Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. Psychopharmacology (Berlin) 164, 341-348. (Pubitemid 35435709)
28. Kong E.K., Peng L., Chen Y., Yu A.C. and Hertz L. (2002) Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochemical Research 27, 113-120. (Pubitemid 34242437)
29. Li Q., Ma L., Innis R.B., Seneca N., Ichise M., Huang H. et al. (2004) Pharmacological and genetic characterization of two selective serotonin transporter ligands: 2-[2-(dimethylaminomethylphenylthio)]- 5- fluoromethylphenylamine (AFM) and 3-amino-4-[2- (dimethylaminomethyl-phenylthio) ]benzonitrile (DASB). Journal of Pharmacology and Experimental Therapeutics 308, 481-486. (Pubitemid 38134208)
30. Li B., Zhang S., Li M., Hertz L. and Peng L. (2009) Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2Binduced, transactivation-mediated ERK1/2 phosphorylation. Psychopharmacology (Berlin) 207, 1-12.
31. Li B., Zhang S., Li M., Hertz L. and Peng L. (2010) Serotonin increases ERK(1/2) phosphorylation in astrocytes by stimulation of 5-HT(2B) and 5-HT(2C) receptors. Neurochemistry International (E-Pub.) 5, 2010.
32. Li B., Zhang S., Zhang H., Nu W., Cai L., Hertz L. et al. (2008) Fluoxetine-mediated 5-HT(2B) receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation. Psychopharmacology (Berlin) 201, 443-458.
33. Liu X., Van Natta K., Yeo H., Vilenski O., Weller P.E., Worboys P.D. et al. (2009) Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid. Drug Metabolism and Disposition: The Biological Fate of Chemicals 37, 787-793.
34. Lovatt D., Sonnewald U., Waagepetersen H.S., Schousboe A., He W., Lin J.H. et al. (2007) The transcriptome and metabolic gene signature of protoplasmic astrocytes in the adult murine cortex. The Journal of Neuroscience 27, 12255-12266. (Pubitemid 350085462)
35. Manev H., Uz T. and Manev R. (2003) Glia as a putative target for antidepressant treatments. Journal of Affective Disorders 75, 59-64. (Pubitemid 36645020)
36. Martensson B., Nyberg S., Toresson G., Brodin E. and Bertilsson L. (1989) Fluoxetine treatment of depression. Clinical effects, drug concentrations and monoamine metabolites and N-terminally extended substance P in cerebrospinal fluid. Acta Psychiatrica Scandinavica 79, 586-596. (Pubitemid 19168605)
37. Meier E., Hertz L. and Schousboe A. (1991) Neurotransmitters as developmental signals. Neurochemistry International 19, 1-15.
38. Meyer J.H., McMain S., Kenedy S.H., Korman L., Brown G.M., DaSilva J.N., Wilson A.A., Blak T., Eynan-Harvey R., Goulding V.S., Houle S. and Links P. (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. American Journal of Psychiatry 160, 90-99. (Pubitemid 36042431)
39. Meyer J.H., Kapur S., Eisfeld B., Brown G.M., Houle S., DaSilva J. et al. (2001) The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. American Journal of Psychiatry 158, 78-85. (Pubitemid 32047250)
40. Meyer J.H., Wilson A.A., Sagrati S., Hussey D., Carella A., Potter W.Z. et al. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. American Journal of Psychiatry 161, 826-835. (Pubitemid 38625335)
41. Nilsson M., Hansson E. and Ronnback L. (1991) Adrenergic and 5-HT2 receptors on the same astroglial cell. A microspectrofluorimetric study on cytosolic Ca2+ responses in single cells in primary culture. Brain Research. Developmental Brain Research 63, 33-41.
42. Peng L., Li B., Du T., Kong E.K., Hu X., Zhang S. et al. (2010) Astrocytic transactivation by alpha(2)-adrenergic and 5-HT(2B) serotonergic signaling. Neurochemistry International, May 7, Epub ahead of print.
43. Pickel V.M. and Chan J. (1999) Ultrastructural localization of the serotonin transporter in limbic and motor compartments of the nucleus accumbens. Journal of Neuroscience 19, 7356-7366. (Pubitemid 29404592)
44. Poblete J.C. and Azmitia E.C. (1995) Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: involvement of the 5-HT2A receptor. Brain Research 680, 9-15.
45. Rao J.S., Ertley R.N., Lee H.J., Rapoport S.I. and Bazinet R.P. (2006) Chronic fluoxetine upregulates activity, protein and mRNA levels of cytosolic phospholipase A2 in rat frontal cortex. Pharmacogenomics Journal 6, 413-420. (Pubitemid 44811537)
46. Reis M. and Kallen B. (2010) Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychological Medicine. Jan. 5, Epub ahead of print.
47. Rhodes C.J., Davidson A., Gibbs J.S., Wharton J. and Wilkins M.R. (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacology and Therapeutics 121, 69-88.
48. Rothman R.B. and Baumann M.H. (2009) Serotonergic drugs and valvular heart disease. Expert Opinion on Drug Safety 8, 317-329.
49. Rothman R.B., Baumann M.H., Savage J.E., Rauser L., McBride A., Hufeisen S.J. et al. (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841.
50. Sanden N., Thorlin T., Blomstrand F., Persson P.A. and Hansson E. (2000) 5-Hydroxytryptamine2B receptors stimulate Ca2+ increases in cultured astrocytes from three different brain regions. Neurochemistry International 36, 427-434. (Pubitemid 30101584)
51. Sawamura K., Suzuki Y. and Someya T. (2004) Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. European Journal of Clinical Pharmacology 60, 553-557. (Pubitemid 39517907)
52. Seki M., Nawa H., Morioka T., Fukuchi T., Oite T., Abe H. et al. (2002) Establishment of a novel enzyme-linked immunosorbent assay for Thy-1; quantitative assessment of neuronal degeneration. Neuroscience Letters 329, 185-188. (Pubitemid 34880069)
53. Sit D.K., Perel J.M., Helsel J.C. and Wisner K.L. (2008) Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. Journal of Clinical Psychiatry 69, 652-658. (Pubitemid 351792342)
54. Sublette M.E., Milak M.S., Hibbeln J.R., Freed P.J., Oquendo M.A., Malone K.M. et al. (2009) Plasma polyunsaturated fatty acids and regional cerebral glucose metabolism in major depression. Prostaglandins, Leukotrienes and Essential Fatty Acids 80, 57-64.
55. Tatsumi M., Groshan K., Blakely R.D. and Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology 340, 249-258. (Pubitemid 28022649)
56. van Harten J. (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics 24, 203-220. (Pubitemid 23094387)
57. Voineskos A.N., Wilson A.A., Boovariwala A., Sagrati S., Houle S., Rusjan P. et al. (2007) Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berlin) 193, 539-545. (Pubitemid 47094376)
58. Weissman A.M., Levy B.T., Hartz A.J., Bentler S., Donohue M., Ellingrod V.L. et al. (2004) Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. American Journal of Psychiatry 161, 1066-1078. (Pubitemid 38735993)
59. Wille S.M., Cooreman S.G., Neels H.M. and Lambert W.E. (2008) Relevant issues in the monitoring and the toxicology of antidepressants. Critical Reviews in Clinical Laboratory Sciences 45, 25-89. (Pubitemid 351299653)
60. Wilson A.A., Ginovart N., Hussey D., Meyer J. and Houle S. (2002) In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. Nuclear Medicine and Biology 29, 509-515. (Pubitemid 34667112)
61. Wong D.T. and Bymaster F.P. (1995) Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Advances in Experimental Medicine and Biology 363, 77-95.
62. Yu N., Martin J.L., Stella N. and Magistretti P.J. (1993) Arachidonic acid stimulates glucose uptake in cerebral cortical astrocytes. Proceedings of the National Academy of Sciences of the U.S.A. 90, 4042-4046. (Pubitemid 23134162)